 Received systemic therapy with radionuclides e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or Radium Ra 223 dichloride for the treatment of bony metastases No prior invasive malignancy within the prior two years. However, patients with an early stage malignancy that is not expected to require treatment in the next 2 years such as early stage, resected breast cancer or asymptomatic prostate cancer are eligible Untreated brain metastases. Any other serious illness or medical condition that in the investigators opinion would interfere with protocol treatment, such as but not limited to: Any active infection National Cancer Institute Common Terminology Criteria for Adverse Events NCI-CTCAE version 4 Grade 2: Cardiac failure New York Heart Association NYHA III or IV Women who are pregnant or breast-feeding. Inability to comply with the protocol andor not willing or who will not be available for follow-up assessments. 